TAKTakedaRunning, no new patients
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 2
- Patients
- 27 (final count)
- Started
- Nov 12, 2021
- Main results expected
- Jun 16, 2024
- Fully finished
- Dec 20, 2038
- Results posted
- Aug 12, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Measured over: Up to 24 months
Number of Participants With Clinically Significant Changes in Laboratory Parameters
Measured over: Up to 24 months
Number of Participants With Notable Changes in Vital Signs
Measured over: Up to 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05020015 · record last updated 2026-03-31 · checked 2026-11-09 15:47 UTC